281 10291. Yang Y, Herrup K. Cell division in the CNS: protective response or lethal event in post mitotic neurons? Biochim Biophys Acta 2007,1772:457 466. Yang Y, Geldmacher DS, Herrup Maraviroc CCR5 inhibitor K. DNA replication precedes neuronal cell death in Alzheimer,s disease. J Neurosci 2001,21:2661 2668. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer,s disease. J Neurosci 2003,23:2557 2563. Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer,s disease and amyloid precursor protein transgenic mouse models. J Neurosci 2006,26:775 784. Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2006,7:241 245.
Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T, Kameda M, Uozumi T, Tajiri N, Morimoto T, Jing M, Baba T, Wang F, Leung H, Matsui T, Miyoshi Y, Date I. Neuroprotective effects of edaravone administration Aprepitant on 6 OHDA treated dopaminergic neurons. BMC Neurosci 2008,9:75. Zdanys K, Tampi RR. A systematic review of off label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008,32:1362 1374. Zhang Y, Qu D, Morris EJ, O,Hare MJ, Callaghan SM, Slack RS, Geller HM, Park DS. The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin. J Neurosci 2006,26:8819 8828. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM. Insulindegrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer,s disease intervention.
J Neurosci 2004,24:11120 11126. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer,s disease: the two hit hypothesis. Lancet Neurol 2004,3:219 226. Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two hit hypothesis: an update. Biochim Biophys Acta 2007,1772:494 502. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle related events in Alzheimer disease. J Neuropathol Exp Neurol 2000,59:880 888. Liu et al. Page 18 Neurobiol Dis. Author manuscript, available in PMC 2011 March 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript Liu et al.
Page 19 Table 1 Agents that interfere with mitogenic signaling pathways and molecules of the expanded cell cycle.Target Agent Stage/CNS Diseases Tau solvent TRx 0014 Clinical use in AD. Antioxidants Edaravone NXY 059 Coenzyme Q10 Vitamin E Melatonin Trolox SOD NAC PBN Clinical use in stroke in Asia Clinical trials in stroke, AD, ALS. Experimental trials in ALS, PD, SCI. Glutamatergic modulators Riluzole Ceftriaxone Talampanel MK 801 NBQX Clinical use in ALS. Clinical trials in ALS. Experimental trials in ICH, stroke. NMDA receptor modulators Memantine Clinical use in AD. Clinical trials in ALS. Off label use in psychiatric disorders. IL 1 inhibitors Kineret Rytvela Experimental trials in hypoxic ischemic newborn brain injury. TNF inhibitors Thalidomide CNI 1493 Experimental trials in AD, PD, stroke.
Thrombin inhibitors Hirudin Experimental trials in ICH. Thrombin receptor 1 antagonist BMS 200261 Experimental trials in stroke, PD. Secretase inhibitors OM 99 1 OM 99 2 BMS 289948 BMS 299897 Experimental trials in AD. i/eNOS inhibitors l NAME AMT NPA Experimental trials in ICH, SCI. Cox 2 inhibitors Rofecoxib Celecoxib NS 398 Clinical trials in AD. Experimental trials in ICH. Ras inhibitors Exoenzyme C3 Lovastatin Experimental trials in motor neuron disorders. Ca2 channel blockers Flunarizine Clinical trials in stroke. Calpain inhibitors MDL 28170 Experimental trials in AD. Src Inhibitors P
Related posts:
- Imatinib CGP-57148B es acute outcomes after experimental intracerebral hemorrhage
- BMS-536924 IGF-1R inhibitor transfected with the EGFRvIII
- Volasertib BI6727 is subject to final editing, composition, and examining
- ATPase pathway resulted in the identification of another biofilm inhibitor
- Asenapine patients with a baseline CCyR or PCyR who maintained their response post baseline